Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WALTHAM, Mass., Feb. 03, 2016 -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, President and COO of TESARO, will present at the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria in New York City on February 10, 2016 at 2:40 PM Eastern time.
A live webcast of this presentation will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived replay of the webcast will be available on the Company’s website for 14 days following the conference.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
